DaVita (DVA) Projected to Post Earnings on Wednesday

Key Points

• DaVita is projected to report its Q3 2025 earnings on Wednesday, October 29th, with expected earnings of $3.29 per share and revenue of $3.4285 billion.
• The company's previous earnings report revealed a net margin of 6.35% and revenue growth of 6.1% compared to the same quarter a year ago.
• Multiple analysts have lowered their target price for DaVita, with Barclays setting a new target of $149.00 and Bank of America lowering theirs to $140.00, indicating widespread caution among analysts.

DaVita (NYSE:DVA - Get Free Report) is expected to post its Q3 2025 results after the market closes on Wednesday, October 29th. Analysts expect DaVita to post earnings of $3.29 per share and revenue of $3.4285 billion for the quarter. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS.Individuals can find conference call details on the company's upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Wednesday, October 29, 2025 at 5:00 PM ET.

DaVita (NYSE:DVA - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $2.95 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.70 by $0.25. The business had revenue of $3.38 billion during the quarter, compared to analyst estimates of $3.36 billion. DaVita had a return on equity of 369.39% and a net margin of 6.35%.DaVita's revenue for the quarter was up 6.1% compared to the same quarter last year. During the same period last year, the company earned $2.00 EPS. On average, analysts expect DaVita to post $11 EPS for the current fiscal year and $13 EPS for the next fiscal year.

DaVita Stock Up 0.3%

Shares of NYSE:DVA opened at $128.44 on Wednesday. The firm has a market cap of $9.18 billion, a P/E ratio of 12.63, a P/E/G ratio of 0.92 and a beta of 1.13. DaVita has a 12-month low of $122.93 and a 12-month high of $179.60. The business has a fifty day simple moving average of $132.39 and a 200 day simple moving average of $137.98.

Hedge Funds Weigh In On DaVita

Hedge funds and other institutional investors have recently modified their holdings of the business. Canada Pension Plan Investment Board purchased a new position in shares of DaVita in the 2nd quarter worth approximately $43,000. NewEdge Advisors LLC boosted its stake in shares of DaVita by 20.8% in the 1st quarter. NewEdge Advisors LLC now owns 511 shares of the company's stock worth $78,000 after buying an additional 88 shares during the last quarter. Boothbay Fund Management LLC purchased a new position in shares of DaVita in the 2nd quarter worth approximately $213,000. Hudson Bay Capital Management LP purchased a new position in shares of DaVita in the 2nd quarter worth approximately $239,000. Finally, Bayesian Capital Management LP purchased a new position in shares of DaVita in the 2nd quarter worth approximately $256,000. Hedge funds and other institutional investors own 90.12% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. Barclays lowered their target price on DaVita from $160.00 to $149.00 and set an "equal weight" rating for the company in a research report on Thursday, October 9th. Wall Street Zen lowered DaVita from a "buy" rating to a "hold" rating in a research report on Saturday, October 11th. Truist Financial set a $140.00 price objective on DaVita in a research report on Tuesday, October 14th. Bank of America lowered their price objective on DaVita from $145.00 to $140.00 and set an "underperform" rating for the company in a research report on Wednesday, September 10th. Finally, Weiss Ratings reissued a "hold (c+)" rating on shares of DaVita in a research report on Wednesday, October 8th. Four analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of "Reduce" and a consensus price target of $153.25.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.